` XXII (22nd Century Group Inc) vs S&P 500 Comparison - Alpha Spread

XXII
vs
S&P 500

Over the past 12 months, XXII has underperformed S&P 500, delivering a return of -99% compared to the S&P 500's 11% growth.

Stocks Performance
XXII vs S&P 500

Loading

Performance Gap
XXII vs S&P 500

Loading
XXII
S&P 500
Difference

Performance By Year
XXII vs S&P 500

Loading
XXII
S&P 500
Add Stock

Competitors Performance
22nd Century Group Inc vs Peers

22nd Century Group Inc
Glance View

Market Cap
12.6m USD
Industry
Tobacco

22nd Century Group, Inc. is a biotechnology company, which develops disruptive plant-based solutions the for life science, consumer product, and pharmaceutical markets. The company is headquartered in Williamsville, New York and currently employs 76 full-time employees. The company went IPO on 2006-10-17. The firm is focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. In tobacco, hemp/cannabis, and hop plants, it uses various plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits. The company has developed very low nicotine content (VLNC) tobacco and cigarettes, which contain 95% less nicotine than conventional tobacco and cigarettes. Its reduced nicotine cigarettes include VLN King and VLN Menthol King. In hemp, the Company is developing hemp varieties with increased levels of certain cannabinoids and other desirable agronomic traits.

XXII Intrinsic Value
4.26 USD
Undervaluation 76%
Intrinsic Value
Price
Back to Top